Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine for myocardial injury in liver transplantation
NCT03013634Unknown
- Sponsor
- Tianjin First Central Hospital
- Start
- Oct 2016
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of dexmedetomidine in Myocardial injury (2 arms), sponsored by Tianjin First Central Hospital. Primary endpoints: Peri-operative mortality at 5 weeks and Incidence of cardiac complications at 24 hours. Status: unknown.
02
Drugs
dexmedetomidine
03
Conditions
Myocardial injury
Beyond the preview
Go deeper on NCT03013634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03013634.